Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 2004

View Archived Issues

First safety review completed for phase II study of HepeX-B

Target enrollment reached in ARISE study of AGI-1067 for atherosclerosis

MedImmune and Medarex to develop antibodies for autoimmune diseases

Cenomed licenses analogues for cognitive disorders from Medical College of Georgia

GSK profiles CNS pipeline

Enrollment temporarily suspended in phase III surgical study of Inactine system

Phase I data supports the use of IMOxine in cancer immunotherapy

GlaxoSmithKline to develop NS-2359 for depression

Trigen and Eurand to develop controlled-release TGN-167

Japanese launch of Valixa for CMV retinitis

New dosage forms of AG-013736

Coumarinolignoid composition for use as hepatoprotective agent described in patent

Agent for fungal infections and cancer isolated from lichen

Scientists at Aventis claim new azetidinone and its use as a treatment for hyperlipidemia

Novel cathepsin K inhibitors in early development at Sankyo

New insulin secretagogues claimed in Bayer patent

Indian researchers isolate antibacterial agent from Cymbopogon flexuosus

Novel agent by Microbia shows antinociceptive effects in animal models of visceral pain

Neuronal Shp2 tyrosine phosphatase targeted for the treatment of obesity

Chondroprotective effects of glucosamine analogue against osteoarthritis

Bifunctional small molecules inhibit Abeta aggregation

Ferumoxtran-10 improves MRI detection of metastatic nodes in bladder cancer

Antihypertensive effects found for rosiglitazone in diabetics with hypertension

Merimepodib increases virological response to interferon plus ribavirin therapy in hepatitis C

HepeX-B reduces viral load of patients with chronic HBV infection

Two-year data on the effects of statins on glycemic control

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 11, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...